|
| 3-[(5-CHLORO-2-HYDROXYPHENYL)METHYL]-5-[4-(TRIFLUOROMETHYL)PHENYL]-1,3,4-OXADIAZOL-2(3H)-ONE Basic information |
Product Name: | 3-[(5-CHLORO-2-HYDROXYPHENYL)METHYL]-5-[4-(TRIFLUOROMETHYL)PHENYL]-1,3,4-OXADIAZOL-2(3H)-ONE | Synonyms: | 3-[(5-CHLORO-2-HYDROXYPHENYL)METHYL]-5-[4-(TRIFLUOROMETHYL)PHENYL]-1,3,4-OXADIAZOL-2(3H)-ONE;BMS 191011;3-(5-chloro-2-hydroxybenzyl)-5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one;3-(5-chloro-2-hydroxybenzyl)-5-(4-(trifluoroMethyl)phenyl)-1,3,4;-5-(4-(trifluoromethyl);-1,3,4-oxadiazol-2(3H);BMS-191011 >=98% (HPLC);1,3,4-Oxadiazol-2(3H)-one, 3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]- | CAS: | 202821-81-6 | MF: | C16H10ClF3N2O3 | MW: | 370.71 | EINECS: | | Product Categories: | | Mol File: | 202821-81-6.mol | |
| 3-[(5-CHLORO-2-HYDROXYPHENYL)METHYL]-5-[4-(TRIFLUOROMETHYL)PHENYL]-1,3,4-OXADIAZOL-2(3H)-ONE Chemical Properties |
Boiling point | 444.0±55.0 °C(Predicted) | density | 1.51±0.1 g/cm3(Predicted) | storage temp. | Store at RT | solubility | DMSO: soluble20mg/mL, clear (warmed) | pka | 9.27±0.43(Predicted) | form | powder | color | white to beige |
Hazard Codes | T | Risk Statements | 25 | Safety Statements | 45 | RIDADR | UN 2811 6.1 / PGIII | WGK Germany | 3 |
| 3-[(5-CHLORO-2-HYDROXYPHENYL)METHYL]-5-[4-(TRIFLUOROMETHYL)PHENYL]-1,3,4-OXADIAZOL-2(3H)-ONE Usage And Synthesis |
Description | BMS 191011 is an activator of large-conductance calcium-activated potassium (KCa1.1/BK) channels that increases maximum potassium current to 126% of control in X. laevis oocytes expressing human KCa1.1 channels when used at a concentration of 1 μM. In vivo, BMS 191011 (10-100 μg/kg, i.v.) increases the diameter of retinal arterioles without affecting blood pressure or heart rate in rats, an effect that is reversed by the KCa1.1 channel blocker iberiotoxin . | Uses | BMS 191011, is a potent opener of the large-conductance, Ca2+-activated potassium (maxi-K) channel. It has also shown neuroprotective properties in two distinct animal models of stroke- MCAO in the SHR rat and a normotensive model of focal stroke. | Definition | ChEBI: 3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-one is a member of (trifluoromethyl)benzenes. | Biological Activity | Potent Maxi-K channel opener (large-conductance Ca 2+ -activated potassium channel, K Ca 1.1, BK Ca ). Neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke). | storage | Room temperature | references | [1]. hewawasam p, ding m, chen n, et al. synthesis of water-soluble prodrugs of bms-191011: a maxi-k channel opener targeted for post-stroke neuroprotection. bioorganic & medicinal chemistry letters, 2003, 13(10): 1695-1698. [2]. valverde ma, rojas p, amigo j, et al. acute activation of maxi-k channels (hslo) by estradiol binding to the β subunit. science, 1999, 285(5435): 1929-1931. [3]. zhang y, bonnan a, bony g, et al. dendritic channelopathies contribute to neocortical and sensory hyperexcitability in fmr1-/y mice. nature neuroscience, 2014, 17(12): 1701-1709. [4]. gu xq, pamenter me, siemen d, et al. mitochondrial but not plasmalemmal bk channels are hypoxia-sensitive in human glioma. glia, 2014, 62(4): 504-513. [5]. mori a, suzuki s, sakamoto k, et al. bms-191011, an opener of large-conductance ca2+-activated potassium channels, dilates rat retinal arterioles in vivo. biological and pharmaceutical bulletin, 2011, 34(1): 150-152. [6]. romine jl, martin sw, meanwell na, et al. 3-[(5-chloro-2-hydroxyphenyl) methyl]-5-[4-(trifluoromethyl) phenyl]-1, 3, 4-oxadiazol-2 (3 h)-one, bms-191011: opener of large-conductance ca2+-activated potassium (maxi-k) channels, identification, solubility, and sar. journal of medicinal chemistry, 2007, 50(3): 528-542. |
| 3-[(5-CHLORO-2-HYDROXYPHENYL)METHYL]-5-[4-(TRIFLUOROMETHYL)PHENYL]-1,3,4-OXADIAZOL-2(3H)-ONE Preparation Products And Raw materials |
|